Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 20 · below the Ichimoku cloud · RSI 38 · MACD below its signal
| 0.0416 | Previous week high | +2500.00% |
| 0.0416 | Previous week low | +2500.00% |
| 0.0416 | Previous month high | +2500.00% |
| 0.0416 | 52-week high | +2500.00% |
| 0.001600 | Price now | |
| 0.001600 | R3 (classic) | −0.00% |
| 0.001600 | R2 (classic) | −0.00% |
| 0.001600 | R1 (classic) | −0.00% |
| 0.001600 | Pivot | −0.00% |
| 0.001600 | S1 (classic) | −0.00% |
| 0.001600 | S2 (classic) | −0.00% |
| 0.001600 | S3 (classic) | −0.00% |
| 0.001600 | Previous day high | −0.00% |
| 0.001600 | Previous day low | −0.00% |
| 0.001600 | Previous month low | −0.00% |
| 0.000100 | 52-week low | −93.75% |
None of the 29 investors followed here reported a position in AFFY in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a AFFY trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for AFFY.
TimeframesMixed on the daily, weekly and monthly.
pulling back under the 21 EMA
pulling back under the 21 EMA
bouncing over the 21 EMA
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 25.0 | 0.0 | 0.0 | 0.0 | 30.0 | 15.4 | 6.7 | 0.0 | 0.0 | +100.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.5 | 0.0 | -11.1 | 0.0% |
| 2024 | 16.7 | 200.0 | -66.7 | 0.0 | 0.0 | 200.0 | -66.7 | 0.0 | 0.0 | 14.3 | 0.0 | 0.0 | +33.3% |
| 2023 | 150.0 | -60.0 | 0.0 | 2.5 | 0.0 | 0.0 | 2.4 | 4.8 | -4.5 | -92.9 | 100.0 | 0.0 | −85.0% |
| 2022 | 3.3 | -1.6 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -35.5 | −33.3% |
| 2021 | 0.8 | -0.9 | -29.9 | 20.8 | -28.7 | -4.3 | -31.5 | -19.0 | -99.4 | 900.0 | 150.0 | 20.0 | −94.0% |
| 2020 | 74.0 | -8.0 | -37.5 | 0.6 | 41.6 | -10.1 | -26.3 | 236.9 | 190.6 | -38.3 | 56.7 | -55.2 | +300.0% |
| 2019 | 188.5 | -20.0 | -10.0 | -29.6 | 5.3 | 0.0 | -14.5 | 28.1 | -16.9 | -12.1 | 6.3 | 47.1 | +92.3% |
| 2018 | 0.6 | -10.3 | -35.0 | -16.7 | 16.9 | -11.2 | 22.2 | 63.6 | -30.4 | 1.1 | -6.7 | -26.6 | −51.1% |
| 2017 | -9.1 | 1.9 | -8.6 | -5.6 | 9.0 | -6.5 | -13.5 | 2.2 | -4.3 | -29.3 | -32.5 | 26.6 | −58.3% |
| 2016 | 13.5 | 1.5 | 11.9 | -11.5 | -8.6 | 0.0 | 2.7 | 5.2 | -7.4 | 6.7 | 3.7 | -23.1 | −11.4% |
| 2015 | 36.5 | 9.6 | -20.1 | -15.8 | -9.9 | 4.4 | -3.6 | -15.8 | 18.0 | 15.3 | -11.3 | -22.6 | −28.3% |
| 2014 | 14.1 | 6.7 | -15.8 | -32.5 | 29.6 | -85.5 | -1.5 | 120.0 | -31.8 | -26.7 | 77.3 | -48.5 | −87.1% |
| 2013 | -0.9 | -85.9 | -48.1 | -34.5 | 131.1 | -42.3 | 44.2 | -9.8 | -12.8 | -16.9 | -24.8 | -8.2 | −95.9% |
| 2012 | 20.9 | 27.8 | 15.0 | 11.7 | 7.9 | -8.9 | 26.0 | 9.0 | 19.1 | 8.2 | 7.2 | -22.3 | +187.3% |
| 2011 | 0.2 | -4.2 | -8.0 | 11.4 | 8.3 | -3.0 | -3.8 | -29.0 | -4.5 | 18.8 | -0.9 | 25.4 | −0.6% |
| 2010 | -15.1 | -11.0 | 25.3 | 1.7 | -7.7 | -72.8 | 7.5 | -12.6 | 5.9 | -14.8 | 33.3 | -1.6 | −73.1% |
| 2009 | 30.1 | 0.6 | 23.2 | 10.1 | -4.2 | 8.4 | 3.7 | 19.2 | 4.9 | -15.7 | 1.2 | 21.4 | +147.6% |
| 2008 | -10.3 | -4.0 | -26.8 | 9.6 | -3.5 | 6.7 | 28.3 | -8.2 | 5.9 | -32.5 | -13.1 | -14.2 | −55.3% |
| 2007 | 8.2 | 0.5 | -9.5 | 5.9 | -6.9 | -16.2 | -9.0 | -3.7 | 11.6 | 5.1 | -10.5 | -12.2 | −34.3% |
No analyst coverage for this instrument.
Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.
No recent headlines.